An interventional study of High fructose, fructose labeled meal and High fructose, pyruvate labeled meal in Insulin Resistance, Insulin Sensitivity and Pre Diabetes, sponsored by Touro University, California. Active, not recruiting at 1 site in United States. Open to participants aged 20 Years to 55 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2026-11-12.
Sponsored by Touro University, California · Not applicable, Interventional, and Basic science
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 1,118 studies in Insulin Resistance with a site in United States — 117 open to participants now, 149 under way, 2 of them phase 3. Insulin Resistance · United States.
Among the 1,118 studies in Insulin Resistance with a site in United States, this one is the 482nd largest by enrollment of the 936 interventional ones that give a count, is one of 43 that started in 2019, is one of 535 with no phase, reaches primary completion later than 66 of the 146 other live ones, and was the 878th registered.
2,974 studies on the registry are indexed under Insulin Resistance; 336 are open to participants now.
Browse Insulin Resistance studies →117 of the 1,118 studies in Insulin Resistance with a site in United States are open now. Recruiting first, the newest first:
National Institute on Aging (NIA) · Sites in United States
Ages 55–100
HealthPartners Institute · Sites in United States
Ages 18–65
Regeneron Pharmaceuticals · Sites in United States
Ages 18–75
University of Colorado, Denver · Sites in United States
Ages 14–19
St. Louis University · Sites in United States
Ages 18–69
A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →
Of the 241 Insulin Resistance studies recruiting now, 52 (22%) set no upper age limit and 157 (65%) stop at 75 or younger; 28 take children under 18; 112 take healthy volunteers.
This study: 20 Years to 55 Years · all sexes · healthy volunteers too.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
1,118 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 137 · Phase 2 162 · Phase 3 45 · Phase 4 100
First in 1976; this study’s year is marked. 43 started in 2019.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 35 is below the median of 40 across 2,371 interventional studies indexed under Insulin Resistance.
Median enrollment 37 across the 936 interventional studies, 48 across the 174 observational. Of the 872 that completed or were terminated, 311 (36%) have results posted.
This tab as a report to print or save as PDF → With an account.
93 of 1,118 have an industry lead sponsor. The 10 most frequent:
Touro University, California is the lead sponsor of 7 studies on the registry; 2 are open to participants now.
Touro University, California has 1 study filed under Insulin Resistance — fewer than ten, so there is no comparison to draw.
53 of the studies in Insulin Resistance with a site in United States that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT03947697University of Texas, El PasoImproving Glycemic Control With Electrical Stimulation | 2026-11-25 |
| NCT05958368Pennington Biomedical Research CenterAssessing the Value of Avocados on Glycemic Control in Type 2 Diabetes | 2026-11-30 |
| NCT05441982Virginia Polytechnic Institute and State UniversitySaccharin and Acesulfame Potassium Consumption and Glucose Homeostasis in Older Adults With Prediabetes | 2026-11-30 |
| NCT03318094Vanderbilt University Medical CenterRole of Sympathetic Vasoconstriction on Insulin-Mediated Microvascular Recruitment and Glucose Uptake in Obesity | 2026-11-30 |
| NCT05165706Stanford UniversityLongitudinal Multi-Omic Profiles to Reveal Mechanisms of Obesity-Mediated Insulin Resistance | 2026-11-30 |
Add all 53 to your calendar (.ics) → With an account.
Among the 1,118 studies in Insulin Resistance with a site in United States, from their registry updates:
This tab as a report to print or save as PDF → With an account.
This objective of this study is to use sensitive methodology under controlled conditions to investigate the mechanisms by which fructose consumption contributes to excess fatty acid synthesis and elevations in blood glucose levels following consumption of meals containing fructose.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
A blood test of average blood sugar over the past two to three months, given as a percentage or in mmol/mol. 6.5% (48 mmol/mol) or more is the usual threshold for diabetes, normally confirmed by a second test.
Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.
Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.
The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.
“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.
The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
BMI (body mass index)
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
HbA1c
A blood test of average blood sugar over the past two to three months, given as a percentage or in mmol/mol. 6.5% (48 mmol/mol) or more is the usual threshold for diabetes, normally confirmed by a second test.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ALT and AST (liver enzymes)
Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.
Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ULN (upper limit of normal)
The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.
“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hemoglobin (Hb)
The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
HIV
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
2-13C fructose incorporated into a meal with high fructose content
Other: High fructose, fructose labeled meal
2-13C pyruvate incorporated into a meal with high fructose content
Other: High fructose, pyruvate labeled meal
2-13C fructose incorporated into a meal with low fructose content
Other: Low fructose, fructose labeled meal
2-13C pyruvate incorporated into a meal with low fructose content
Other: Low fructose, pyruvate labeled meal
Liquid meal containing high fructose (16% of energy), labeled with 2-13C fructose
Liquid meal containing high fructose (16% of energy), labeled with 2-13C pyruvate
Liquid meals containing low fructose (6% of energy), labeled with 2-13C fructose
Liquid meal containing low fructose (6% of energy), labeled with 2-13C pyruvate
Hepatic fractional de novo lipogenesis in triglyceride rich lipoprotein (TRL)
Measured by the detection of 13C carbons in TRL-palmitate from administered 13C labeled pyruvate or 13C labeled fructose.
Time frame: 6 hours
Rate of appearance of UDP-glucose
An estimate of hepatic glycogen flux measured by administration of D1 galactose and acetaminophen
Time frame: 6 hours
Rate of appearance of blood glucose from gluconeogenesis
Measured by the dilution method of labeled glucose
Time frame: 6 hours
Serum triglyceride concentration
Fasting and postprandial serum triglyceride levels
Time frame: 6 hours
Serum glucose concentration
Fasting and postprandial serum triglyceride levels
Time frame: 6 hours
Serum lactate concentration
Fasting and postprandial serum lactate levels
Time frame: 6 hours
Serum insulin concentration
Fasting and postprandial insulin levels
Time frame: 6 hours
Serum free fatty acid concentration
Fasting and postprandial fatty acid levels
Time frame: 6 hours
Enteral (chylomicron) fractional de novo lipogenesis (DNL)
Measured by the detection of 13C carbons in chylomicron-palmitate from administered 13C labeled pyruvate or 13C labeled fructose.
Time frame: 6 hours
Hepatic (VLDL) fractional de novo lipogenesis (DNL)
Measured by the detection of 13C carbons in VLDL-palmitate from administered 13C labeled pyruvate or 13C labeled fructose.
Time frame: 6 hours
Extrasplanchnic fructose
Calculated using total plasma fructose, plasma 2-13C fructose enrichment, and endogenous fructose production
Time frame: 6 hours
Whole body fructose oxidation
Measured by 13C atom % excess in exhaled breath, and VCO2 by indirect calorimetry
Time frame: 6 hours
Started Sep 2019 (actual). Primary completion is estimated for Jun 2027, 93 months after the start.
Of 715 non-industry interventional studies with no phase under Insulin Resistance, half reached primary completion within 22 months of starting (the median), counting those still running; a quarter within 10 and three quarters within 41. This study's planned 93 months is above that.
Counting every sponsor, half of 755 studies reached it within 21 months; a quarter within 9 and three quarters within 40.
Since we started tracking on Sep 25, 2026, the dates moved once, on Nov 12, 2026: primary completion Dec 2026 → Jun 2027 and completion Jul 2027 → Dec 2027.
Earlier changes are on the record history on ClinicalTrials.gov ↗
How these figures are worked out, and which studies are left out of them.
From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗
This study is active, not recruiting, as verified in Oct 2026. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Touro University, California